TScan Therapeutics, Inc. TCRX
0.34
(0.01)
(2.86%)
as of 25 Sep
- Market cap
- $23.7M
- P/E
- 0.0×
Follow TCRX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
12.57 | 120.90 | 17.80 | 3.04 | 5.18 | 2.45 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
(4.06) | (12.42) | (15.76) | (2.57) | (3.65) | (1.36) | — | — |
P/B ratio |
1.05 | 1.41 | 2.48 | 0.41 | 0.33 | 0.00 | — | — |
Price to Tangible BV |
1.05 | 1.41 | 2.48 | 0.41 | 0.33 | 0.00 | — | — |
EV/Sales |
1.96 | 32.94 | 10.10 | (3.39) | (10.14) | (14.23) | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.75 | 2.27 | 2.68 | — | — |
EV/Operating CF |
(0.15) | (0.84) | (3.46) | 0.69 | 2.11 | 2.51 | — | — |
EV/FCF |
(0.14) | (0.81) | (3.30) | 0.65 | 1.76 | 1.95 | — | — |
Quick Ratio |
8.15 | 8.07 | 6.44 | 6.94 | 7.56 | 1.99 | 17.43 | — |
Current Ratio |
8.41 | 8.14 | 6.51 | 7.17 | 7.76 | 2.09 | 17.69 | — |
Net Debt/EBITDA |
0.90 | 1.97 | 1.84 | 1.42 | 3.43 | 1.09 | 2.69 | — |
Debt/Assets |
14.22% | 8.64% | 11.04% | 16.56% | 3.21% | 14.95% | 9.90% | 0.00% |
Debt/Equity |
0.26 | 0.13 | 0.20 | 0.33 | 0.04 | (0.18) | (0.29) | — |
Asset Turnover |
0.03 | 0.01 | 0.09 | 0.07 | 0.09 | 0.02 | 0.00 | — |
Operating CF/Net income |
1.04 | 0.87 | 0.69 | 1.00 | 1.00 | 0.12 | 0.92 | — |
Capex/Depreciation |
(1.54) | (0.93) | (0.59) | (0.82) | (2.99) | (3.45) | (2.40) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (71.28%) | (65.08%) | (71.29%) | (50.90%) | (82.20%) | 87.67% | 45.83% | — | |
| (43.26%) | (39.64%) | (37.87%) | (34.21%) | (40.89%) | (52.72%) | (55.31%) | — | |
ROIC |
(2,610.99%) | 0.00% | 0.00% | (336.46%) | (561.31%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(88.14%) | (48.29%) | (51.82%) | (56.64%) | (31.15%) | (105.96%) | (32.81%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
1,105.57% | 3,812.14% | 418.80% | 441.96% | 443.29% | 1,896.50% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
309.81% | 1,075.53% | 125.20% | 150.37% | 136.36% | 621.29% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
113.38% | 339.10% | 24.74% | 33.62% | 24.81% | 47.47% | 0.00% | — |
Graham Net Nets |
0.40 | 0.48 | 0.19 | 0.60 | 2.64 | (5.49) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.48 | — | — |
Earnings Yield |
(100.00%) | (37.83%) | (33.10%) | (160.82%) | (92.71%) | (280.02%) | — | — |
Free Cash Flow Yield |
(107.67%) | (33.68%) | (17.22%) | (172.00%) | (111.69%) | (297.80%) | — | — |
Revenue per Share |
0.08 | 0.03 | 0.32 | 0.56 | 0.87 | 1.18 | 0.00 | — |
Operating CF per Share |
(1.04) | (0.99) | (0.94) | (2.77) | (4.17) | (3.30) | (32.52) | — |
Capex per Share |
(0.03) | (0.03) | (0.05) | (0.18) | (0.85) | (4.63) | (3.24) | — |
Free Cash Flow per Share |
(1.08) | (1.02) | (0.98) | (2.94) | (5.03) | (7.93) | (35.76) | — |
Cash per Share |
1.17 | 2.59 | 2.93 | 4.99 | 13.84 | 37.98 | 108.48 | — |
Shareholders Equity per Share |
0.95 | 2.15 | 2.30 | 4.13 | 13.79 | (46.36) | (44.51) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.95 | 2.15 | 2.30 | 4.13 | 13.79 | (46.36) | (44.51) | — |
Free Cash Flow |
(139.73) | (114.65) | (64.50) | (70.73) | (58.62) | (7.26) | (13.77) | — |
Working Capital |
138.51 | 256.77 | 164.42 | 106.82 | 144.31 | 19.00 | 39.98 | — |
Capital Expenditures |
(4.41) | (3.82) | (3.15) | (4.22) | (9.94) | (4.24) | (1.25) | — |
Net Current Asset Value |
51.54 | 162.57 | 72.96 | 24.47 | 138.33 | (55.75) | (24.14) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.69 | 2.12 | 2.53 | — | — |
Capex to Sales |
0.43 | 1.36 | 0.15 | 0.31 | 0.98 | 3.91 | 0.00 | — |
Net Profit Margin |
(1,256.81%) | (4,527.66%) | (423.86%) | (489.26%) | (479.49%) | (2,408.02%) | 0.00% | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.33 | 0.57 | 0.69 | 0.51 | 0.28 | 0.22 | 0.32 | — |
Cash ROIC |
(46.75%) | (20.96%) | (18.53%) | (30.35%) | (18.41%) | 3,663.29% | (47.99%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | 0.00 | — |
Average Payables |
2.76 | 3.33 | 2.64 | 2.34 | 2.34 | 1.96 | 1.96 | — |
Average Assets |
299.95 | 321.63 | 235.62 | 193.60 | 118.92 | 49.56 | 24.69 | — |
Average Common Equity |
182.05 | 195.92 | 125.15 | 130.11 | 59.16 | (29.80) | (29.80) | — |
Columns are period end dates